BFM
RLMD icon

Boothbay Fund Management’s Relmada Therapeutics RLMD Stock Holding History

Boothbay Fund Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-136,500
Closed -$5.05M – 2387
2022
Q3 		$5.05M Buy
136,500
+100,100
+275% +$2.77M 0.13% 191
2022
Q2 		$691K Buy
+36,400
New +$794K 0.02% 1002

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boothbay Fund Management's RLMD Position: Q1 2026 in Review

Boothbay Fund Management reduced its Relmada Therapeutics (RLMD) stake by 13% in Q1 2026, selling an estimated $503K and leaving 729,055 shares worth $5.07M. The position accounts for 0.07% of the portfolio, ranked #315.

Boothbay Fund Management first reported a position in RLMD in Q1 2021 and has held it in 8 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Boothbay Fund Management held 729,055 shares of Relmada Therapeutics worth $5.07M as of Q1 2026.
  • Boothbay Fund Management sold 106,245 Relmada Therapeutics shares in Q1 2026, an estimated $503K.
  • Relmada Therapeutics made up 0.07% of Boothbay Fund Management's portfolio in Q1 2026, its #315 holding.
  • Boothbay Fund Management first reported a position in Relmada Therapeutics in Q1 2021 and has held it in 8 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.